A prospective observational study of Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma
Latest Information Update: 14 Jun 2022
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms ELIXIR
- 03 Mar 2021 New trial record